32nd week of 2022 patent applcation highlights part 27 |
Patent application number | Title | Published |
20220251197 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2022-08-11 |
20220251198 | CD200R AGONIST ANTIBODIES AND USES THEREOF - The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis. | 2022-08-11 |
20220251199 | METHODS FOR ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 AGENTS - Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject. | 2022-08-11 |
20220251200 | EXTRACELLULAR VESICLES TARGETING T CELLS AND USES THEREOF - The present disclosure relates to modified extracellular vesicles, e.g, exosomes, comprising a targeting moiety (e.g., anti-CD3 targeting moiety), wherein the targeting moiety can specifically bind to markers expressed on distinct immune cells (e.g., T cells). Also provided herein are methods for using the exosomes to treat and/or prevent a range of medical disorders. | 2022-08-11 |
20220251201 | DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient. | 2022-08-11 |
20220251202 | FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN BINDING MOLECULES FOR MODULATING IMMUNE CELL FUNCTION - Provided herein are fusion proteins that bind human CD8α, human CD8β, or human PD1 and comprise a mutant IL-2 polypeptide, as well as polynucleotides, host cells, compositions, and methods of use thereof. | 2022-08-11 |
20220251203 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH FAMITINIB IN PREPARATION OF DRUG FOR TREATING TUMORS - The present disclosure provides the use of an anti-PD-1 antibody in combination with famitinib in the preparation of a drug for treating tumors. In the present technical solution, toxicity is controllable and tolerable. At the same time, the described drug combination effectively reduces adverse reactions to the anti-PD-1 antibody, such as the occurrence of reactive capillary endothelial proliferation. | 2022-08-11 |
20220251204 | BISPECIFIC BINDING PROTEINS AND USES THEREOF - The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject. | 2022-08-11 |
20220251205 | COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF OBTAINING THE COMPOSITIONS THEREOF - The invention provides compositions of anti-PD-1 antibodies or antigen-binding fragments thereof with less than or equal to about 3.0% oxidation of Met105 in the CDRH3 heavy chain region, and methods of obtaining the purified compositions. The invention also provides compositions comprising anti-PD-1 antibody main species and acidic species thereof, wherein the amount of acidic species is about 1.0-12.0%. | 2022-08-11 |
20220251206 | ANTI-CTLA4 ANTIBODY PRODRUGGABLE (PROBODY) AT A CDR POSITION - An anti-CTLA4 antibody can be prodrugged by replacement of certain complementarity determining region (CDR) amino acids with a cysteine (Cys), which provides a chemical functionality for attachment of a blocking moiety that can be cleaved at the site of intended action, thus releasing the un-prodrugged antibody. | 2022-08-11 |
20220251207 | SUBSTANCE AND METHOD FOR TREATING TUMOR - Disclosed are a method for treating a tumor using a CTLA4-binding protein and a use thereof, wherein the CTLA4-binding protein specifically binds to CTLA4 and does not compete with a ligand of CTLA4 for binding to CTLA4. The CTLA4-binding protein described in the present application can effectively inhibit tumor growth. | 2022-08-11 |
20220251208 | Caninized Antibodies Against Canine CTLA-4 - The present invention provides caninized murine antibodies against canine CTLA-4 that have specific sequences and a high binding affinity for canine CTLA-4. The present invention further provides epitopes of canine CTLA-4 for caninized murine antibodies against canine CTLA-4.5 The invention also relates to use of these antibodies in the treatment of cancer in canines and other companion animals. | 2022-08-11 |
20220251209 | CANINIZED ANTIBODIES TO HUMAN CTLA-4 - The present invention provides caninized anti-human CTLA-4 antibodies that have specific sequences and a high binding affinity for canine CTLA-4. The invention also relates to use of these antibodies in the treatment of cancer in canines and other companion animals. | 2022-08-11 |
20220251210 | FORMULATION COMPRISING ANTI-CD47/PD-L1 BISPECIFIC ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOF - The present invention relates to formulations comprising an anti-CD47/PD-L1 bispecific antibody, and in particular to pharmaceutical formulations comprising an anti-CD47/PD-L1 bispecific antibody, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of these formulations. | 2022-08-11 |
20220251211 | A NOVEL ANTI-PD-L1 ANTIBODY AND USE THEREOF - Provided is an isolated antibody or antigen-binding fragment thereof that binds specifically to human CD-L1 protein, a nucleic acid molecule encoding the same, therapeutic compositions thereof, and their use to treat a PD-L1 related disease, such as a tumor which is PD-L1 positive. | 2022-08-11 |
20220251212 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS - The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy. | 2022-08-11 |
20220251213 | Anti-B7-H4 Antibodies and Immunoconjugates - The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same. | 2022-08-11 |
20220251214 | Bispecific Antibodies for Activation of Immune Cells - The invention provides bispecific antibodies having one arm binding to a cancer associated antigen on a cancer cell, such as CD33, EGFR or PD-L1, and a second arm binding to a costimulatory molecule, such as OX40, CD40, GITR, ICOS or 4-1BB. Bridging by the bispecific antibody between cancer cells expressing the cancer associated antigen and immune cells expressing the costimulatory molecule results in clustering of the costimulatory molecules and selective activation of the immune cells at a location proximate to the cancer cells. Thus, the immune cells can exert an immunotherapeutic effect against the cancer cells with reduced toxicity to healthy tissue. | 2022-08-11 |
20220251215 | ANTI-NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA 1 (NY-ESO-1) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF - The present disclosure provides antigen-binding proteins that specifically bind to an H LA-displayed New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide, and therapeutic and diagnostic methods of using those binding proteins. The antigen-binding proteins of the present disclosure bind with a high degree of specificity to HLA-displayed NY-ESO-1 and do not bind to HLA-displayed peptides that differ by 2, 3, 4, 5 or more amino acids. | 2022-08-11 |
20220251216 | ANTI HLA-G SPECIFIC ANTIBODIES - The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the α3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies. | 2022-08-11 |
20220251217 | IMMUNOTHERAPY TARGETING CELL SURFACE MARKER CD72 FOR THE TREATMENT OF B-CELL MALIGNANCIES - Provided herein are anti-CD72 nanobodies and methods of using such nanobodies for diagnostic and therapeutic purposes. | 2022-08-11 |
20220251218 | PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING IMMUNE RESPONSE AGAINST CANCER - The invention relates to a method of overcoming immune suppression in tumor microenvironment or stimulating immune response against cancer, comprising administering to a subject a combination of a histone deacetylase (HDAC) inhibitor and a tyrosine kinase inhibitor (TKI). | 2022-08-11 |
20220251219 | METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof. | 2022-08-11 |
20220251220 | N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES - Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs. | 2022-08-11 |
20220251221 | IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES - Antigen binding molecules capable of binding to CD122 and/or common γ chain (CD132) are disclosed herein. Also disclosed are compositions comprising such antigen binding molecules, and uses and methods using the same. | 2022-08-11 |
20220251222 | IL-6Ralpha/IL-8R BISPECIFIC BINDING AGENTS FOR INHIBITING CANCER CELL MIGRATION - The present disclosure relates to bispecific binding agents with a novel format that bind IL-6Rα and IL-8R. The present disclosure also relates to methods of using such bispecific binding agents in the treatment of cancer. | 2022-08-11 |
20220251223 | BISPECIFIC BINDING AGENTS - Provided herein are novel bispecific binding agents and methods of constructing and expressing the same. The methods of constructing the bispecific binding agent generally describes a combination of a knobs-in-holes assembly strategy and a single-chain Fab expression approach to generate a modular bispecific binding platform. | 2022-08-11 |
20220251224 | CAR-CD123 VECTOR AND USES THEREOF - The present invention relates to a chimeric antigen receptor (CAR) molecule containing, from the N-terminus to the C-terminus: a) an extracellular domain and transmembrane domain of human CD19, b) an antigen binding domain, c) a spacer domain, d) a transmembrane domain, and e) a cytoplasmatic domain, preferably wherein the CAR is a CD123 specific CAR (CD123 CAR) and the antigen binding domain includes a VL and/or VH from a monoclonal anti-CD123 antibody, more preferably the antigen binding domain includes a single chain variable fragment (scFv) that specifically binds to CD123. | 2022-08-11 |
20220251225 | MODIFIED ANTIBODY CONSTANT REGION - The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fcγ receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics. | 2022-08-11 |
20220251226 | ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND APPLICATION THEREOF - A group of anti-BCM single domain antibodies, as well as genes of the single domain antibodies in the group, a vector containing the single domain antibodies in the group, a chimeric antigen receptor, and a T cell modified by a chimeric antigen receptor, and detection and treatment application of the single domain antibodies in the group. The anti-BCMA single domain antibodies have high activity, high stability, high specificity, and high binding capability. | 2022-08-11 |
20220251227 | GITR ANTAGONISTS AND METHODS OF USING THE SAME - The present disclosure relates to compounds that bind to human GITR, pharmaceutical compositions comprising such compounds, and methods of using such compounds. | 2022-08-11 |
20220251228 | ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF - Provided are an anti-BCMA antibody, an antigen-binding fragment thereof, and a medical use thereof. Further provided are a chimeric antibody and a humanized antibody containing a CDR region of the anti-BCMA antibody, a pharmaceutical composition containing the anti-BCMA antibody or the antigen-binding fragment thereof, and the use of same as an anti-cancer drug and for treating autoimmune diseases. Particularly, provided are a humanized anti-BCMA antibody, and the use of same in the preparation of a drug for treating BCMA-mediated diseases or conditions and the use of same in disease detection and diagnosis. | 2022-08-11 |
20220251229 | ANTI-TNFRSF9 ANTIBODIES AND USES THEREOF - This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof. | 2022-08-11 |
20220251230 | MONOCLONAL ANTIBODIES AND METHODS OF USE - This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs. | 2022-08-11 |
20220251231 | BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF - CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions. | 2022-08-11 |
20220251232 | NOVEL ANTI-CD25 ANTIBODIES - Novel anti-CD25 antibodies and antigen-bind fragments thereof that do not inhibit the binding of interleukin-2 (IL-2) to CD25, and the use thereof for treating cancer or an infectious disease. Also, fusion proteins including the antibodies and antigen-bind fragments, nucleic acids encoding the antibodies and antigen-bind fragments, and an expression vectors including the nucleic acids. Further, pharmaceutical compositions including the fusion proteins or the antibodies and antigen-bind fragments. | 2022-08-11 |
20220251233 | ANTI-CD53 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF - The present invention is based, in part, on the discovery of anti-CD53 compositions (e.g., monoclonal antibodies and antigen-binding fragments thereof), that regulate inflammatory phenotypes of myeloid cells, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-CD53 compositions for therapeutic, diagnostic, prognostic, and screening purposes. | 2022-08-11 |
20220251234 | ANTIBODIES HAVING SPECIFICITY FOR CD38 AND USES THEREOF - CD38 is also expressed in a variety of malignant hematological diseases, including multiple myeloma. In the present invention, the inventors have generated a new antibody against CD38 that could be suitable for producing bispecific antibodies as well as CAR-T cells. In particular, the inventors report the development of Bi38-3, a new bispecific T cell engager that targeted CD38 on MM cells and recruited cytotoxic T cells through the CD3ε. Bi38-3 lacked the Fc region of natural mAb, which contributes to resistance processes, but triggered T cells to proliferate, release cytokine and lyse CD38 positive MM cells in vitro. Similarly, Bi38-3 induced autologous T cells to eliminate tumor plasma cells isolated from MM patients both at diagnosis and at relapse. The cytotoxicity triggered by Bi38-3 was restricted to cells expressing high levels of CD38 and preserved the integrity of T, B and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in an MM1.S xenograft mouse model of human MM. Taken together, the results show that the antibody of the present invention is an effective reagent to specifically eliminate CD38 positive malignant cells without significantly affecting CD38 lowly expressing cells and represents a promising novel immunotherapeutic tool for the treatment of malignant hematological diseases, and especially multiple myeloma. | 2022-08-11 |
20220251235 | MAGEA10 SPECIFIC T CELL RECEPTORS AND THEIR USE - The present invention relates to an isolated T cell receptor (TCR) specific for a MAGEA10-derived peptide and to a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer. | 2022-08-11 |
20220251236 | MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT - The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases. | 2022-08-11 |
20220251237 | Antibody Specific for GPC3 and Methods of Use Thereof - The present disclosure provides antibodies specific for glypican-3 (GPC3). Nucleic acids that encode one or both of the variable chain polypeptides of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are useful in various diagnostic, and monitoring applications, which are also provided. | 2022-08-11 |
20220251238 | BISPECIFIC ANTIGEN-BINDING CONSTRUCT AND PREPARATION METHOD AND USE THEREOF - Disclosed are a bispecific antigen-binding construct and the preparation method and use thereof, wherein the construct comprises a first antigen binding unit and a second antigen binding unit, the first antigen binding unit is a single chain variable region antibody fragment ScFV which specifically binds to the surface antigen of immune cells, and the second antigen binding unit is a Slit2D2 protein fragment which specifically binds to the surface antigen Robo1 of tumour cells. That is to say, the construct can bind to the surface antigen of immune cells and the surface Robo1 molecule of tumour cells at the same time, so that as the distance between tumour cells and immune cells get smaller, the quiescent immune cells are effectively activated, and the effect of killing and wounding tumours is produced. The construct has advantages of small molecular weight and good tissue penetrability, has significant killing and wounding effects on the tumour cells which express a large amount of Robo1, and can be used in the development of anti-tumour drugs. | 2022-08-11 |
20220251239 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER - Provided are compositions and methods for treating cancers and precancerous proliferative disorders in a mammalian subject that involve the combination use of a radiotherapeutic agent, such as a radiolabeled CD33, DR5, 5T4, HER2, HER3, or TROP2 targeting agent, and a CD47 checkpoint inhibitor, such as a SIRPα-IgG Fc fusion protein or a monoclonal antibody against CD47 or SIRPα. | 2022-08-11 |
20220251240 | Antibodies for Botulinum Neurotoxins - The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 2022-08-11 |
20220251241 | HTRA1-BINDING AGENTS AND METHODS OF USE THEREOF - The present disclosure provides binding agents, such as antibodies, that specifically bind HTRA1, including human HTRA1, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising and expressing the binding agents. | 2022-08-11 |
20220251242 | MODIFIED ANTIGEN BINDING POLYPEPTIDE CONSTRUCTS AND USES THEREOF - The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the C | 2022-08-11 |
20220251243 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 2022-08-11 |
20220251244 | Multispecific Antigen-Binding Molecules for Cell Targeting and Uses Thereof - The present invention provides multispecific antigen-binding molecules that bind both a T-cell antigen (e.g., CD3) and a target antigen (e.g., a tumor associated antigen, a viral or bacterial antigen), and which include a single polypeptide chain that is multivalent (e.g., bivalent) with respect to T-cell antigen binding, and uses thereof. | 2022-08-11 |
20220251245 | PROCESS FOR PRODUCING A CELLULOSIC FUNCTIONAL FIBRE WITH HIGH ION EXCHANGE CAPACITY, CELLULOSIC FUNCTIONAL FIBRE, TEXTILE PRODUCT COMPRISING CELLULOSIC FUNCTIONAL FIBRE, AND GARMENT OR PIECE OF FURNITURE COMPRISING SAID CELLULOSIC FUNCTIONAL FIBRE OR TEXTILE PRODUCT - A process for producing a cellulosic functional fiber having high ion exchange capacity, a cellulosic functional fiber produced by said process, a textile product comprising said cellulosic functional fiber, and a garment or piece of furniture comprising said cellulosic functional fiber and/or said textile product. The cellulosic functional fiber produced is characterized in that it comprises an extracted plant material with polymer-bound uronic acids contained therein. | 2022-08-11 |
20220251246 | CARBOXYTERMINATED DIENE RUBBERS - The invention relates to carboxyterminated diene rubbers, their production and use. | 2022-08-11 |
20220251247 | METHOD FOR PRODUCING HOLLOW RESIN PARTICLES - A method for producing hollow resin particles, the method comprising a mixture liquid preparation step, a suspension preparation step, a polymerization step, and a solvent removal step; wherein a content of a saturated hydrocarbon solvent is 50% by mass or more with respect to 100% by mass of a total amount of a hydrocarbon solvent; wherein a polymerization initiator is an oil-soluble polymerization initiator; and wherein, in the mixture liquid, a cross linkable monomer contains a tri- or higher functional crosslinkable monomer, and with respect to 100 parts by mass of a total amount of the polymerizable monomer, a total content of the crosslinkable monomer is 80 to 98 parts by mass, a content of the tri- or higher functional crosslinkable monomer is from 10 parts by mass to 98 parts by mass, and a content of the hydrocarbon solvent is from 300 parts by mass to 1500 parts by mass. | 2022-08-11 |
20220251248 | METHOD FOR PRODUCING AN AQUEOUS POLYMER DISPERSION FROM A VINYL AROMATIC COMPOUND AND A CONJUGATED ALIPHATIC DIENE - The present invention relates to a process for preparing an aqueous polymer dispersion by radically initiated aqueous emulsion polymerization, which comprises polymerizing | 2022-08-11 |
20220251249 | ACTIVE ENERGY RAY CROSSLINKABLE THERMOPLASTIC POLYMER AND COMPOSITION CONTAINING THE SAME - The present invention provides a polymer which has a polymerizable functional group but still can be thermoformed without being crosslinked and which undergoes crosslinking upon irradiation with an active energy ray after being formed, and a composition including the polymer. An active energy ray crosslinkable thermoplastic polymer includes specific monomer units (1). The ratio of the number of moles of the monomer units represented by the general formula (1) to the number of moles of all monomer units constituting the polymer is not less than 1 mol %. The number average molecular weight (Mn) of the active energy ray crosslinkable thermoplastic polymer is 20,000 to 500,000. | 2022-08-11 |
20220251250 | PHOTOCURABLE RESIN COMPOSITION WITH LOW SHRINKAGE AND HIGH ACCURACY FOR USE IN ADDITIVE MANUFACTURING PROCESSES - A photo-curable resin composition is suitable for the fabrication of 3D printed objects via digital light processing (DLP) or stereolithography (SLA). The photo-curable resin composition can provide 3D printed objects having lower volumetric shrinkage, high accuracy and favorable mechanical strength for dental application such as building models, implant templates, surgical guides, night guard/occlusal splints, dentures, clear aligners, and temporary restorations. | 2022-08-11 |
20220251251 | FLUOROPOLYMER AQUEOUS DISPERSION PRODUCTION METHOD AND FLUOROPOLYMER AQUEOUS DISPERSION - A method for producing a purified fluoropolymer aqueous dispersion, which includes: (A) bringing a fluoropolymer aqueous dispersion obtained using a hydrocarbon surfactant into contact with an anion exchange resin A or a synthetic adsorbent. The anion exchange resin A has an ion-exchange group represented by the following general formula (A1): | 2022-08-11 |
20220251252 | TRACEABLE COMPOSITE POLYMERS AND PREPARATION METHODS THEREOF - The present invention is in the field of polymers comprising XRF identifiable tracers allowing information to be encoded by the polymers, and in particular polymers for conservation, restoration and retouching in artworks, electronics, coatings, plastics etc. | 2022-08-11 |
20220251253 | DIAPHRAGM FOR MINIATURE SOUND GENERATING DEVICE AND MINIATURE SOUND GENERATING DEVICE - A diaphragm for a miniature sound generating device, wherein the diaphragm is made of a polyacrylate copolymer, a plasticizer is mixed in the polyacrylate copolymer, the polyacrylate copolymer is 100 parts by mass, and the plasticizer comprises at least one of aliphatic dibasic acid esters, phthalic acid esters, benzene polyacid esters, benzoic ethers, polyol esters, chlorinated hydrocarbons, epoxides, citrate esters and polyesters. The diaphragm possesses excellent sound performance. | 2022-08-11 |
20220251254 | MALEIMIDE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT - To provide a curable resin composition of which a cured product has excellent heat-resistance and dielectric properties, and a cured product thereof, and a prepreg, a circuit board, a build-up film, a semiconductor sealing material, and a semiconductor apparatus having both excellent heat resistance and dielectric properties. The invention has an indane scaffold represented by the following general formula (1): | 2022-08-11 |
20220251255 | LOW DENSITY POLYETHYLENE WITH IMPROVED PROCESSABILITY - A low density polyethylene (LDPE) having a z-average molecular weight Mz (cony) from 425,000 g/mol to 800,000 g/mol, a melt index I | 2022-08-11 |
20220251256 | LONG-CHAIN BRANCHED PROPYLENE POLYMER COMPOSITION - The present invention relates to a propylene polymer composition comprising a long chain branched propylene polymer, wherein said propylene polymer composition has a) a melt flow rate MFR | 2022-08-11 |
20220251257 | HYDROGEN BOND INDUCED HIGH STABILITY POROUS COVALENT ORGANIC GEL MATERIAL AND PREPARATION METHOD THEREOF - A hydrogen bond induced high stability porous covalent organic gel material and a preparation method thereof are provided. The method comprises: dissolving tetrakis(4-carboxyphenyl)silane in methanol to obtain solution A; adding concentrated sulfuric acid to the solution A, then water-bath heating and re-flowing to obtain a solution B; evaporating the solution B, dissolving remaining powder with an ethyl acetate, washing and drying, filtering and then evaporating the filtrate until crystallization to obtain a colorless solid C; dissolving the colorless solid C and hydrazine hydrate in methanol, water-bath re-fluxing, filtering and collecting white powder, washing and drying to obtain a white solid D; adding the white solid D and 1,4-Phthalaldehyde to N,N-dimethyl-formamide, adding trifluoroacetic acid, and then getting the desired material. The material is has high synthesis efficiency, abundant functional groups, a large specific surface area, a good adsorption performance, and excellent chemical stability and thermal stability. | 2022-08-11 |
20220251258 | POLYETHYLENE COPOLYMERS AND PRODUCTS AND METHODS THEREOF - A polymer composition may include a polymer produced from ethylene, one or more branched vinyl ester monomers, and optionally, vinyl acetate; wherein the polymer has a number average molecular weight ranging from 5 to 10,000 kDa, and a molecular weight distribution ranging from 1 to 60, obtained by GPC. | 2022-08-11 |
20220251259 | C2C3 RANDOM COPOLYMER COMPOSITION | 2022-08-11 |
20220251260 | PROPYLENE-ETHYLENE-alpha-OLEFIN COPOLYMER, POLYPROPYLENE COMPOSITION, AND USE THEREFOR - A propylene-ethylene-α-olefin copolymer satisfying: (I) a content of a propylene-derived constituent unit (i) is 50 to 92 mol %, a content of an ethylene-derived constituent unit (ii) is 5 to 20 mol %, and a content of a C4-20 α-olefin-derived constituent unit (iii) is 3 to 30 mol %, provided that (i) to (iii) total 100 mol %; (II) an mm fraction calculated by | 2022-08-11 |
20220251261 | LIPID NANODISCS SOLUBILIZED THROUGH POLY(ACRYLIC ACID-CO-STYRENE) COPOLYMERS - Provided herein are compositions including lipids and copolymers in the form of a nanodisc assembly. The subject copolymers include monomer units of styrene and monomer units selected from acrylic acid and an acrylic acid derivative. In certain cases, the copolymer is a copolymer of styrene and acrylic acid. Also provided herein, is an aqueous solution comprising the subject composition. Also provided herein, are methods for producing a nanodisc assembly, including incubation of a lipid and a subject copolymer. Further provided herein, are methods for solubilizing a membrane protein in an aqueous solution, wherein the method includes forming a nanodisc assembly of a lipid bilayer having one or more membrane proteins embedded therein, and a subject copolymer. Also provided are methods of solubilizing a hydrophobic constituent in an aqueous solution, including forming a nanodisc assembly of a lipid, a hydrophobic constituent, and a subject copolymer. | 2022-08-11 |
20220251262 | COMPRESSED MEMBER FOR ELECTROCHEMICAL DEVICE - Provided is a member to be compressed for an electrochemical device obtained by crosslinking a crosslinkable composition containing a fluorine-containing elastomer, wherein the fluorine-containing elastomer exhibits a difference δG′ (G′(100° C.)−G′(180° C.)) between the storage elastic modulus G′(100° C.) at a measurement temperature of 100° C. and the storage elastic modulus G′(180° C.) at a measurement temperature of 180° C., in the dynamic viscoelasticity test (strain amplitude: 0.5 Deg; frequency: 100 CPM) with a rubber process analyzer satisfying the following conditions: | 2022-08-11 |
20220251263 | USE OF A VINYLIDENE FLUORIDE COPOLYMER FOR PROVIDING A FILM WITH PROPERTIES OF ADHESION - The present invention relates to the use of a fluorinated copolymer in the manufacture of a solid polymer film, to give said film properties of adhesion to a metal surface or to glass. It also relates to a process for improving the adhesion of a fluoropolymer to a metal, polymer or glassy substrate, and also to a composite part comprising a solid polymer film in direct contact with at least one metal or glassy element. | 2022-08-11 |
20220251264 | FLUOROSULFONYL GROUP-CONTAINING FLUOROPOLYMER AND METHOD FOR PRODUCING SAME, SULFONIC ACID GROUP-CONTAINING FLUOROPOLYMER AND METHOD FOR PRODUCING SAME, SOLID POLYMER ELECTROLYTE MEMBRANE, MEMBRANE ELECTRODE ASSEMBLY, AND SOLID POLYMER FUEL CELL - The present invention provides a fluoropolymer containing fluorosulfonyl groups capable of forming a polymer electrolyte membrane with high conductivity and hot water resistance, a method for its production, a fluoropolymer containing acid-form sulfonic acid groups and a method for its production, a polymer electrolyte membrane, a membrane-electrode assembly and a polymer electrolyte fuel cell. The method for producing a fluoropolymer containing fluorosulfonyl groups of the present invention comprises copolymerizing a monomer m1 (CF | 2022-08-11 |
20220251265 | ACRYLIC RUBBER BALE EXCELLENT IN PROCESSABILITY AND WATER RESISTANCE - Acrylic rubber bale having remarkably improved storage stability and water resistance without deteriorating cross-linking properties, a method of production, a rubber mixture obtained by mixing the acrylic rubber bale, a method of production, and a rubber cross-linked product obtained by cross-linking the same is provided. The acrylic rubber bale includes an acrylic rubber, and the acrylic rubber is mainly composed of (meth) acrylic acid ester, and has a weight average molecular weight of 100,000 to 5,000,000, and has a ratio of a Z-average molecular weight and a weight average molecular weight of 1.3 or more, where an ash content is 0.6% by weight or less, and the ash contains a periodic table group 2 metal and phosphorus, and a phosphorus content is 10% by weight or more, and the ratio of the periodic table group 2 metal to phosphorus is in the range of 0.6 to 2 molar ratio. | 2022-08-11 |
20220251266 | ACRYLATE-BASED COPOLYMER, METHOD FOR PRODUCING SAID COPOLYMER, FRICTION REDUCER USING SAID COPOLYMER, AND LUBRICATING COMPOSITION CONTAINING SAID FRICTION REDUCER - The present invention provides an acrylate-based copolymer obtained by polymerizing constituent monomers including a polymerizable monomer (a) consisting of an alkyl acrylate-based monomer represented by the following general formula (1) in an amount of from 10 mol % to 95 mol % with respect to a total number of moles of the constituent monomers, a polymerizable monomer (b) consisting of an alkylene glycol acrylate-based monomer represented by the following general formula (2) in an amount of from 5 mol % to 50 mol % with respect to the total number of moles of the constituent monomers, and at least one kind of polymerizable monomer (c) selected from the group consisting of an aromatic vinyl-based monomer (c-1) and a short-chain alkyl acrylate-based monomer (c-2) represented by the following general formula (3) in an amount of from 0 mol % to 60 mol % with respect to the total number of moles of the constituent monomers. In the formula (1), R | 2022-08-11 |
20220251267 | POLYMER AND METHOD FOR PRODUCING SAME, AND RESIN COMPOSITION FOR RESIST - The present invention provides a polymer comprising a structural unit derived from p-hydroxystyrene and a structural unit having a structure in which a carboxylic acid is protected by an acetal group, wherein the structural unit generated by elimination of the acetal group or migration of the acetal group during the production process is extremely small; and a process for producing the same. | 2022-08-11 |
20220251268 | RESIN COMPOSITION FOR INJECTION MOLDING OR COMPRESSION MOLDING - A resin composition for injection molding or compression molding using an ethylene-based ionomer is excellent in impact strength, heat resistance, long-term durability, etc. The resin composition includes an ionomer in which, in a copolymer (P) containing a structural unit (A) derived from ethylene and/or an α-olefin having 3 to 20 carbon atoms, and a structural unit (B) derived from a monomer having a carboxyl group(s) and/or a dicarboxylic anhydride group(s) as essential constitutional units, at least a part of the carboxyl groups and/or the dicarboxylic anhydride groups in the copolymer (P) being converted into a metal-containing carboxylic acid salt(s) containing at least one kind of a metal ion(s) selected from Group 1, Group 2 or Group 12 of the periodic table, and has a phase angle S at an absolute value G*=0.1 MPa of a complex modulus of elasticity measured by a rotary rheometer of 50 degrees to 75 degrees. | 2022-08-11 |
20220251269 | WATER EXTRACTABLE OPHTHALMIC DEVICES - A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more non-bulky organosilicon-containing monomers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group. The water extractable ophthalmic device has an equilibrium water content of at least about 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least about 60 Barrers. | 2022-08-11 |
20220251270 | Hydrocarbon Polymer Modifiers Having Low Aromaticity and Uses Thereof - Described herein are hydrocarbon polymer modifiers for use in various applications. The hydrocarbon polymer modifier comprises a cyclic component, and has a glass transition temperature and Mn defined by the following two equations: (1) Tg≥95-2.2*(% H Ar); and (2) Tg≥125−(0.08*Mn) and an aromaticity content of less than or equal to 6 mole %, wherein Tg is glass transition temperature as expressed in ° C. of the modifier, the % H Ar represents the content of aromatic protons in the hydrocarbon polymer modifier, and Mn represents the number average molecular weight of the hydrocarbon polymer modifier, and the cyclic component is selected from the group of a distillation cut from a petroleum refinery stream, and/or C | 2022-08-11 |
20220251271 | RESIN COMPOSITION FOR PLATING, AND PLATED MOLDED ARTICLE - To provide a resin composition for plating and a plated molded article which are excellent in impact resistance and fluidity and which satisfy plating adhesion strength, plating deposition rate and thermal cycle resistance in a well-balanced manner. | 2022-08-11 |
20220251272 | POLY (ETHYLENE-VINYL ACETATE) COPOLYMER WITH NON-SPECIFIC SPATIAL CONFIGURATION, METHOD FOR ITS PREPARATION AND USE - A new poly (ethylene-vinyl acetate) copolymer with a non-specific spatial configuration of the vinyl acetate units with respect to the main ethylene chain. Also, a method for its production through addition polymerization of polyethylene and vinyl acetate and to its use. The new poly (ethylene-vinyl acetate) copolymer will find application in various branches of the chemical industry and construction. | 2022-08-11 |
20220251273 | MODIFIED POLYVINYL ALCOHOL-BASED POLYMER AND ITS APPLICATION - The present disclosure provides a modified polyvinyl alcohol-based polymer, which comprises a modifying monomer unit represented by Formula | 2022-08-11 |
20220251274 | CURABLE RESIN COMPOSITION, CURED FILM, COATING RESIN MOLDED BODY AND MULTILAYER FILM - To provide a resin composition, which has both a thermosetting property and active energy curability, satisfactory performances, and excellent performances including handleability of being inexpensive without having a concern about a short pot life after blending with a thermal cross-linking agent as in the related art. The curable resin composition contains: a resin component (A) containing a (meth)acryloyl group (a), a hydroxy group (b), and an alkyl ester group (c); and an initiator (B). | 2022-08-11 |
20220251275 | RESIN COMPOSITION FOR STEREOLITHOGRAPHIC MODELING - The present invention provides a resin composition for stereolithographic modeling emitting a weak odor, having desirable shape accuracy, and made into a cured product having desirable strength, toughness, and color tone when used for stereolithographic modeling. The present invention relates to a resin composition for stereolithographic modeling, comprising: a polymerizable monomer (A); a photopolymerization initiator (B), and an organic peroxide (C), wherein the polymerizable monomer (A) comprises a (meth)acrylic acid ester compound (A-1) having a viscosity of 1,000 mPa·s or less and a normal boiling point of 270° C. or more and/or a (meth)acrylamide compound (A-2) having a viscosity of 1,000 mPa·s or less and a normal boiling point of 200° C. or more, and the photopolymerization initiator (B) is at least one selected from a (bis)acylphosphine oxide, an α-hydroxyketone compound, an α-aminoketone compound, a benzoin alkyl ether compound, a thioxanthone, a ketal, an α-diketone, and an anthraquinone. | 2022-08-11 |
20220251276 | POLYCARBONATE-MODIFIED ACRYLIC RESIN, COATING MATERIAL, AND MOLDED PLASTIC ARTICLE COATED WITH SAID COATING MATERIAL - Provided is a polycarbonate-modified acrylic resin that is a reaction product of a polycarbonate diol (A) obtained from 1,4-butanediol as an essential raw material and an unsaturated monomer mixture (B) comprising as essential components methyl methacrylate, an unsaturated monomer (b1) having a hydroxyl group, and an unsaturated monomer (b2) having a carboxyl group, in which a mass ratio of the unsaturated monomer (b2) in the unsaturated monomer mixture (B) is in a range of 2 to 10%. The polycarbonate-modified acrylic resin can form a coating film having high adhesion to a plastic base material, excellent water resistance adhesion, and fragrance resistance, so that it can be suitably used as a coating material for coating various articles. | 2022-08-11 |
20220251277 | ACRYLIC RUBBER SHEET EXCELLENT IN WATER RESISTANCE - An acrylic rubber sheet excellent in storage stability and water resistance, a method for producing the same, a rubber mixture containing the acrylic rubber sheet and a rubber cross-linked product thereof are provided. The acrylic rubber sheet according to the present invention includes an acrylic rubber having a reactive group and having a weight average molecular weight (Mw), a ratio of a Z-average molecular weight (Mz) and a weight average molecular weight (Mw) in a specific range. The acrylic rubber sheet according to the present invention has an ash content of 0.2% by weight or less, an amount of gel insoluble in methyl ethyl ketone is 50% by weight or less, and a water content of less than 1% by weight, and is excellent in water resistance and highly well-balanced in strength properties and processability. | 2022-08-11 |
20220251278 | CURABLE (METH)ACRYLATE COMPOSITIONS - A two-part curable (adhesive) composition comprising a Part A and a Part B:
| 2022-08-11 |
20220251279 | Method for Preparation of Acetoacetate Ester Compounds - The invention discloses a method for preparation of acetoacetate ester compounds with amino alcohol catalysts which are themselves diketenized in the course of the diketenization reaction; and subsequent polymerization of these acetoacetate ester compounds with e.g. acrylate compounds to provide resins, whereby the acetoacetylated amino alcohol catalyst partakes in the polymerization reaction. | 2022-08-11 |
20220251280 | PROCESS OF PREPARING ALLOPHANATE- AND/OR THIOALLOPHANATE GROUP-CONTAINING COMPOUNDS - The invention relates to a process of preparing allophanate- and/or thioallophanate group-containing compounds comprising the following steps: reacting A) at least one component having at least one uretdione group with B) at least one component having at least one hydroxyl and/or thiol group, in the presence C) of at least one catalyst, containing a structural element of the general formulae (I) and/or (II), wherein R | 2022-08-11 |
20220251281 | POLYURETHANE COMPOSITIONS, PRODUCTS PREPARED WITH SAME AND PREPARATION METHODS THEREOF - A polyurethane composition is provided. The polyurethane composition comprises (A) one or more polyurethane-prepolymers prepared by reacting at least one polyisocyanate compound with a first polyol component; and (B) a second polyol component; wherein at least one of the first polyol component and the second polyol component comprises an ester/ether block copolymer polyol synthesized by reacting a starting material polyether polyol with a C | 2022-08-11 |
20220251282 | CHEMICAL RESISTANT PUD FOR MICROFIBER NONWOVEN SYNTHETIC LEATHER APPLICATION AND THE METHOD - The present disclosure provides a polyurethane dispersion comprising a polyurethane prepolymer and an ionic surfactant. It further provides a microfiber nonwoven synthetic leather comprising a microfiber nonwoven fabric and the polyurethane dispersion. It further provides a method of preparing the microfiber nonwoven synthetic leather comprising a step of impregnating microfiber nonwoven fabrics into the polyurethane dispersion. | 2022-08-11 |
20220251283 | Lewis Acid Polymerization Catalyst - A method of producing a polyether alcohol that includes feeding an initiator into a reactor, feeding one or more monomers into the reactor, feeding a polymerization catalyst into the reactor, the polymerization catalyst being a Lewis acid catalyst having a general formula M(R | 2022-08-11 |
20220251284 | 2-PART REACTIVE URETHANE RESIN COMPOSITION AND METHOD FOR PRODUCING THEREOF - Provided is a material having an excellent sound-absorbing performance which can be easily applied to the desired area at the operation site and which can effectively prevent sound leakage. | 2022-08-11 |
20220251285 | CURABLE COMPOSITION, CURED PRODUCT, FIBER-REINFORCED COMPOSITE MATERIAL, AND MOLDED ARTICLE - The present invention provides a curable composition containing a urethane-modified epoxy resin (A) as an essential component of a main agent and an acid anhydride (B) as an essential component of a curing agent, the urethane-modified epoxy resin (A) being a reaction product obtained by using a polyisocyanate compound (a1), a polyether polyol (a2), and a hydroxy group-containing epoxy resin (a3) as essential reaction materials; a cured product thereof; a fiber-reinforced composite material; a fiber-reinforced resin molded article; and a method for producing a fiber-reinforced resin molded article. The curable composition can form a cured product having excellent fracture toughness and tensile strength in the cured product. | 2022-08-11 |
20220251286 | CURING COMPOSITION - The present disclosure relates to a curing composition comprising: a) a condensation product of at least one carboxylic acid having 20-60 carbon atoms and at least two carboxyl groups and/or at least one ester derived from a carboxylic acid having 20-60 carbon atoms and at least two carboxyl groups; and at least one polyoxyalkyleneamine, wherein the polyoxyalkyleneamine includes: I) at least two oxyalkylene moieties; and II) at least two primary amino groups; and b) at least one amine having at least one amino group. Also provided are an adhesive composition comprising the curing composition, usage of the adhesive, a turbine blade for wind energy comprising the adhesive composition, and a method for manufacturing the curing composition. | 2022-08-11 |
20220251287 | PHOTO RADIATION CURABLE EPOXY FOR ELECTRICAL COMPONENTS - An epoxy formulation is provided with improved properties for electrical components exposed to a voltage differential. The improved electrical properties include increased glass transition temperature, increased breakdown strength and/or lower loss factor. Electrical components may be formed from the epoxy formulation by 3D printing the epoxy formulation and curing the formulation with UV radiation. The epoxy formulation includes epoxy, a photoinitiator and an accelerator. | 2022-08-11 |
20220251288 | REPROCESSABLE COMPOSITIONS - The present disclosure provides compositions comprising:
| 2022-08-11 |
20220251289 | METHOD FOR PREPARING AN ELASTOMER FROM A HYDROXYLATED FATTY ACID AND ELASTOMER OBTAINED BY SUCH A METHOD - A method for preparing a polymer of the elastomer type based on a monomer selected from polyhydroxylated fatty acids and esters of a polyhydroxylated fatty acid and a C1-C18 aliphatic chain alcohol is disclosed. This method includes preparing a reaction medium by bringing the monomer with a polyol, this reaction medium being catalyst free, then a step of heating the reaction medium in order to implement the copolymerisation of the monomer and of the polyol and the cross-linking of the polymer thus formed, with at least the initial phase of this heating step being implemented at a reduced pressure. | 2022-08-11 |
20220251290 | MULTI-BLOCK SHAPE MEMORY BIORESORBABLE POLYMERS - This invention relates to the synthesis of multi-block bioresorbable polymers bearing hard and soft polymeric segments. The invention further relates to bioresorbable polymers for shape memory properties. The invention also relates to the use of such polymers as bone filler, vascular closure devices, hemostasis device, aneurysms, mastectomy devices and stent applications. The invention relates also to the use of such polymers for applications in fast degradation applications and 3D printing. The invention also relates to the use of such polymers as drug delivery platforms applications. | 2022-08-11 |
20220251291 | Polybutylene Terephthalate With Low THF Content - The invention relates to the use of polyethylene terephthalate for production of polybutylene terephthalate-based automotive interior parts having a low TVOC content and a low tetrahydrofuran content by injection molding, wherein TVOC stands for “Total Volatile Organic Compounds”. | 2022-08-11 |
20220251292 | PRESSURE SENSITIVE ADHESIVES MADE FROM UV CURING OF PLANT OIL-BASED POLYESTERS - An ultraviolet radiation-curable composition comprising a polyester having at least one pendant ultraviolet radiation-curable moiety covalently bonded to the polyester, wherein the polyester does not contain any free-radically polymerizable activated C═C groups. | 2022-08-11 |
20220251293 | YELLOWING RESISTANT POLYESTER AND METHOD FOR MANUFACTURING THE SAME - A polyester and a method for manufacturing polyester are provided. The polyester comprises one or more repeating units derived from polyols and one or more repeating units derived from polybasic acids and contains phosphorus and a metal element, wherein one or more repeating units derived from polyols include a repeating unit derived from tricyclodecane dimethanol, the weight ratio of the phosphorus to the metal element ranges from 0.05 to 5.00, and the metal element is selected from the group consisting of Ti, Sn, Sb, Ge, Mn, Zn, Ca, Co, Pb, Al, Zr, and combinations thereof. | 2022-08-11 |
20220251294 | POLYESTER RESIN, AND MOLDED ARTICLE, STRETCHED FILM AND BOTTLE COMPRISING THE SAME - A polyester resin contains a dicarboxylic acid constituent unit and a diol constituent unit, wherein more than 0% by mol and 20% by mol or less of the diol constituent unit is a unit originated from a diol having a cyclic acetal skeleton; 70 to 98% by mol of the diol constituent unit is a unit originated from a diol having an alicyclic skeleton; the diol constituent unit comprises a unit originated from ethylene glycol; 80% by mol or more of the dicarboxylic acid constituent unit is a unit originated from terephthalic acid; and the polyester resin has a physical property indicated by the following (A): (A) the minimum value of the semi-crystallization time is 600 s or less based on a depolarized light intensity method when the polyester resin is melted at 280° C. and crystallized at a constant temperature of 150 to 230° C. | 2022-08-11 |
20220251295 | LEVODOPA POLYMERIC CONJUGATES, FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE - Compounds of formula I: or a pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein: R | 2022-08-11 |
20220251296 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS - The present disclosure relates to the field of polymer chemistry and more particularly to multiblock copolymers comprising a poly(sarcosine) block and a D,L-mixed poly(amino acid) block and uses thereof. | 2022-08-11 |